Applied Genetic Technologies Corp. (NASDAQ:AGTC)’s share price shot up 3% during trading on Friday . The company traded as high as $15.84 and last traded at $15.61, with a volume of 63,511 shares. The stock had previously closed at $15.16.

A number of research firms recently commented on AGTC. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price target on shares of Applied Genetic Technologies Corp. in a research note on Wednesday, June 22nd. Zacks Investment Research cut shares of Applied Genetic Technologies Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Wells Fargo & Co. reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a research report on Tuesday, May 10th. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Applied Genetic Technologies Corp. in a research report on Tuesday, May 10th. Finally, Roth Capital reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a research report on Monday, April 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Applied Genetic Technologies Corp. has an average rating of “Buy” and an average target price of $26.00.

The firm’s market capitalization is $282.94 million. The firm has a 50 day moving average of $15.38 and a 200 day moving average of $15.29.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last issued its earnings results on Monday, May 9th. The company reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.06. The business earned $12 million during the quarter, compared to analyst estimates of $12.98 million. Applied Genetic Technologies Corp.’s quarterly revenue was up 4125.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.38) earnings per share. Equities analysts expect that Applied Genetic Technologies Corp. will post ($0.16) earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its stake in Applied Genetic Technologies Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 677,610 shares of the company’s stock valued at $13,823,000 after buying an additional 3,248 shares during the last quarter. Globeflex Capital L P purchased a new stake in Applied Genetic Technologies Corp. during the fourth quarter valued at about $1,189,000. CAM Group Holding A S purchased a new stake in Applied Genetic Technologies Corp. during the fourth quarter valued at about $1,428,000. Finally, Russell Frank Co purchased a new stake in Applied Genetic Technologies Corp. during the fourth quarter valued at about $1,541,000.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.